Equities

Daito Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Daito Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,396.00
  • Today's Change31.00 / 2.27%
  • Shares traded114.50k
  • 1 Year change+36.13%
  • Beta0.7077
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Daito Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture, sale, purchase and sale of active pharmaceutical ingredients and formulations (prescription drugs and over-the-counter drugs), contract manufacturing of active pharmaceutical ingredients and formulations, and sale of health foods and other products. The Company is primarily engaged in the pharmaceutical business segment. The main products are active pharmaceutical ingredients and formulations. The Company manufactures, sells, purchases and sells active pharmaceutical ingredients, which are raw materials used to manufacture pharmaceuticals, and undertakes contract manufacturing. The Company also manufactures, sells, purchases and sells formulations of prescription drugs and over-the-counter drugs, and undertakes contract manufacturing.

  • Revenue in JPY (TTM)51.20bn
  • Net income in JPY2.23bn
  • Incorporated1942
  • Employees1.07k
  • Location
    Daito Pharmaceutical Co Ltd326, Yoka-machiTOYAMA-SHI 939-8567JapanJPN
  • Phone+81 764215665
  • Fax+81 764216006
  • Websitehttps://www.daitonet.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Seikagaku Corp35.86bn-755.00m39.26bn1.08k--0.516829.451.09-13.84-13.84656.961,337.180.43282.033.9233,360,930.00-0.90993.60-0.98813.9640.9252.56-2.107.944.26--0.004955.178.736.57-44.46--18.482.90
Qinghai Spring Medicinl Rsrcs Tech CoLTD6.33bn-2.47bn39.40bn159.00--1.72--6.23-0.1864-0.18640.4961.750.24921.084.071,790,944.00-9.61-15.06-10.10-15.6631.0122.84-38.56-147.188.94-2.610.0045--26.362.9525.80---1.38--
Bliss GVS Pharma Ltd14.68bn1.84bn39.71bn966.0021.80--15.952.7010.1810.1880.97--------8,986,598.00--6.04--7.5452.6546.3313.189.45--8.44--8.275.133.2711.72-2.825.180.00
Laboratorio Reig Jofre SA59.65bn773.21m40.09bn1.42k51.431.0111.320.6720.05210.05214.042.670.93411.885.34231,058.501.242.391.613.1560.4860.251.322.780.99074.940.2265--7.2211.1010.3616.00-7.77--
Lifecore Biomedical Inc-15.35tn-15.35tn40.72bn406.00--------------0.9818-----------7.91---10.85--32.86---23.151.67--0.787--0.4725-4.24-575.39---12.85--
Animalcare Group Plc16.96bn623.68m40.74bn201.0066.181.7217.472.400.04260.04261.241.640.56442.795.78403,343.302.081.332.421.5856.3655.543.682.231.27--0.1566176.024.940.858339.11--4.7120.11
Daito Pharmaceutical Co Ltd51.20bn2.23bn41.08bn1.07k18.340.7746.200.802474.4274.421,703.911,763.620.65442.162.7647,716,680.002.905.123.716.6717.6321.754.437.351.31--0.173924.487.992.39-42.09-13.5220.4514.00
Cipher Pharmaceuticals Inc7.68bn2.66bn41.61bn61.0016.352.3911.165.420.89390.89392.576.120.33222.154.291,118,770.0011.5219.6313.0323.1774.3279.7434.6959.540.97665.740.10520.0057.668.24-43.3634.34127.59--
Abeona Therapeutics Inc61.41m12.64bn41.68bn136.004.531.533.21678.751.111.110.00733.270.0023--0.24782,941.1846.83-62.2352.94-78.23-122.00--20,587.50-1,824.219.53--0.1034---100.00---17.62---17.78--
Pyridam Farma Tbk PT25.72bn-4.40bn42.06bn2.34k--6.29--1.64-76.90-76.90326.2865.220.44014.303.881,450,964,000.00-7.52-1.59-10.76-2.0223.3635.12-17.09-2.650.736-0.48210.8735--173.5950.70-287.52--110.52--
Evolus Inc43.88bn-8.99bn42.79bn329.00------0.9752-0.9125-0.91254.46-0.44411.274.096.01860,912.60-26.11-37.04-36.48-57.1465.8365.19-20.49-51.261.53-2.131.25--31.7650.1218.26--1.10--
Spectral Medical Inc304.53m-4.69bn42.82bn29.00------140.60-0.1455-0.14560.0095-0.23750.3314.437.0393,275.86-510.19-135.57---711.8956.1655.19-1,541.33-581.020.1044-0.1904----43.05-4.430.7223---30.03--
Data as of Feb 17 2026. Currency figures normalised to Daito Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

31.60%Per cent of shares held by top holders
HolderShares% Held
Kaname Capital LP (Investment Management)as of 31 Jul 20253.35m11.13%
MFS International Singapore Pte Ltd.as of 31 Dec 20251.36m4.53%
The Vanguard Group, Inc.as of 04 Feb 2026932.62k3.10%
Nomura Asset Management Co., Ltd.as of 05 Feb 2026848.00k2.82%
Portfolia, Inc.as of 01 Apr 2024821.40k2.73%
Dimensional Fund Advisors LPas of 05 Feb 2026794.47k2.64%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Feb 2026474.28k1.58%
Amova Asset Management Co., Ltd.as of 06 Feb 2026360.60k1.20%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026344.20k1.14%
T&D Asset Management Co., Ltd.as of 25 Apr 2025221.60k0.74%
More ▼
Data from 01 Apr 2024 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.